Results 21 to 30 of about 189,065 (308)

Antiviral Activity of the Chemokine CXCL10 against West Nile Virus

open access: yesIntervirology
Background: West Nile virus (WNV) is an emerging arbovirus for which there is no vaccine nor antiviral treatment. Skin cells are the primary site of WNV replication following transmission by the mosquito vector. In a previous work, strong induction of CXCL10 mRNA expression was observed during in vitro infection of human primary keratinocytes with WNV.
Luc, Deroche   +9 more
openaire   +3 more sources

CXCL10 (chemokine (C-X-C motif) ligand 10) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2012
Review on CXCL10 (chemokine (C-X-C motif) ligand 10), with data on DNA, on the protein encoded, and where the gene is implicated.
Antonicelli, F, Bernard, P
openaire   +3 more sources

Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer. [PDF]

open access: yesJ Immunother Cancer, 2022
Background Although immune checkpoint blockade (ICB) has been proven to achieve a persistent therapeutic response in various tumor types, only 20%–40% of patients benefit from this treatment. Radiotherapy (RT) can enhance tumor immunogenicity and improve
Jie X   +12 more
europepmc   +2 more sources

Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells.

open access: yesTuberculosis, 2015
BackgroundThe role of B cells in human host response to Mycobacterium tuberculosis (Mtb) infection is still controversial, but recent evidence suggest that B cell follicle like structures within the lung may influence host responses through regulation of
S. Hoff   +7 more
semanticscholar   +2 more sources

Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10.

open access: yesBlood, 2012
Myelomonocytic cells play a key role in the progression of many solid tumors. However, very little is known about their contribution to the progression of hematopoietic cancers.
Yunqin Lee   +7 more
semanticscholar   +2 more sources

CD8+ T Cells Produce the Chemokine CXCL10 in Response to CD27/CD70 Costimulation To Promote Generation of the CD8+ Effector T Cell Pool

open access: yesJournal of Immunology, 2013
Various cell types can produce the chemokine CXCL10 in response to IFN-gamma stimulation. CXCL10 is generally viewed as a proinflammatory chemokine that promotes recruitment of CD8(+) and Th1-type CD4(+) effector T cells to infected or inflamed ...
V. Peperzak   +6 more
semanticscholar   +2 more sources

Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.

open access: yesCytokine, 2012
Until now, no data are present in literature about the prototype Th1 chemokine (C-X-C motif) ligand 10 (CXCL10) in anaplastic thyroid cancer (ATC). This study aimed to test in "primary human ATC cells" (ANA) vs "normal thyroid follicular cells" (TFC): (a)
A. Antonelli   +9 more
semanticscholar   +2 more sources

Upregulation of chemokine CXCL10 enhances chronic pulmonary inflammation in tree shrew collagen-induced arthritis. [PDF]

open access: yesSci Rep, 2018
Chronic pulmonary inflammation (CPI) gives rise to serious lung injuries in rheumatoid arthritis (RA) patients. However, the molecular mechanism underlying the pathogenesis of RA-associated CPI remains little understood.
Gao B   +10 more
europepmc   +2 more sources

Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.

open access: yesEndocrine-Related Cancer, 2009
In papillary thyroid carcinomas (PTCs), oncogenes activate a transcriptional program including the upregulation of CXCL10 chemokine, which stimulates proliferation and invasion.
A. Antonelli   +12 more
semanticscholar   +2 more sources

A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by immune effector cells. In particular, NK cell infiltration is often reduced relative
Niklas Muenchmeier   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy